In conclusion, we identified PDPK1 as a novel potential therapeutic target in PCa and demonstrated PDPK1 is mediating PCa cells’ survival through activation of SGK3 in an AKT‐independent manner. Here, SGK3 is linked to posterior cortical atrophy.